Compare Glenmark Pharma with ALEMBIC PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs ALEMBIC PHARMA - Comparison Results

GLENMARK PHARMA     Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA ALEMBIC PHARMA GLENMARK PHARMA/
ALEMBIC PHARMA
 
P/E (TTM) x 15.6 19.6 79.5% View Chart
P/BV x 2.0 5.8 34.4% View Chart
Dividend Yield % 0.5 0.7 76.9%  

Financials

 GLENMARK PHARMA   ALEMBIC PHARMA
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-19
ALEMBIC PHARMA
Mar-19
GLENMARK PHARMA/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs712664 107.2%   
Low Rs484412 117.3%   
Sales per share (Unadj.) Rs349.6208.7 167.5%  
Earnings per share (Unadj.) Rs32.831.0 105.8%  
Cash flow per share (Unadj.) Rs44.337.1 119.5%  
Dividends per share (Unadj.) Rs2.005.50 36.4%  
Dividend yield (eoy) %0.31.0 32.7%  
Book value per share (Unadj.) Rs198.6144.2 137.7%  
Shares outstanding (eoy) m282.17188.52 149.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.72.6 66.3%   
Avg P/E ratio x18.217.4 105.0%  
P/CF ratio (eoy) x13.514.5 92.9%  
Price / Book Value ratio x3.03.7 80.6%  
Dividend payout %6.117.7 34.4%   
Avg Mkt Cap Rs m168,625101,461 166.2%   
No. of employees `00012.0NA-   
Total wages/salary Rs m20,5617,467 275.4%   
Avg. sales/employee Rs Th8,196.0NM-  
Avg. wages/employee Rs Th1,708.1NM-  
Avg. net profit/employee Rs Th768.5NM-  
INCOME DATA
Net Sales Rs m98,65539,347 250.7%  
Other income Rs m2,08194 2,218.9%   
Total revenues Rs m100,73639,441 255.4%   
Gross profit Rs m15,8588,736 181.5%  
Depreciation Rs m3,2591,152 282.8%   
Interest Rs m3,346184 1,817.4%   
Profit before tax Rs m11,3357,493 151.3%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m0-93 0.0%   
Extraordinary Inc (Exp) Rs m1,6720-   
Tax Rs m3,7561,568 239.6%   
Profit after tax Rs m9,2505,844 158.3%  
Gross profit margin %16.122.2 72.4%  
Effective tax rate %33.120.9 158.4%   
Net profit margin %9.414.9 63.1%  
BALANCE SHEET DATA
Current assets Rs m66,96819,577 342.1%   
Current liabilities Rs m40,21114,896 269.9%   
Net working cap to sales %27.111.9 228.0%  
Current ratio x1.71.3 126.7%  
Inventory Days Days8390 92.9%  
Debtors Days Days8145 179.0%  
Net fixed assets Rs m33,32227,097 123.0%   
Share capital Rs m282377 74.9%   
"Free" reserves Rs m55,77026,811 208.0%   
Net worth Rs m56,05227,188 206.2%   
Long term debt Rs m35,7384,993 715.8%   
Total assets Rs m132,88847,778 278.1%  
Interest coverage x4.441.7 10.5%   
Debt to equity ratio x0.60.2 347.2%  
Sales to assets ratio x0.70.8 90.1%   
Return on assets %9.512.6 75.1%  
Return on equity %16.521.5 76.8%  
Return on capital %17.823.6 75.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m62,99819,453 323.9%   
Fx outflow Rs m22,8596,065 376.9%   
Net fx Rs m40,14013,388 299.8%   
CASH FLOW
From Operations Rs m13,2428,120 163.1%  
From Investments Rs m-6,990-7,556 92.5%  
From Financial Activity Rs m-7,387590 -1,251.3%  
Net Cashflow Rs m-2,9711,153 -257.6%  

Share Holding

Indian Promoters % 48.3 74.1 65.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 2.9 237.9%  
FIIs % 34.4 9.1 378.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 13.9 75.5%  
Shareholders   56,727 49,328 115.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   WYETH LTD  IPCA LABS  JUBILANT LIFE SCIENCES  SUN PHARMA  PIRAMAL ENTERPRISES  

Compare GLENMARK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 129 Points Lower; Banking and Finance Stocks Witness Selling(Closing)

Indian share markets witnessed volatile trading activity throughout the day and ended their trading session marginally lower.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 64.0% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 33.3% (Quarterly Result Update)

Jan 23, 2020 | Updated on Jan 23, 2020

For the quarter ended December 2019, ALEMBIC PHARMA has posted a net profit of Rs 2 bn (up 33.3% YoY). Sales on the other hand came in at Rs 12 bn (up 18.8% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 25.2% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 25.2% YoY). Sales on the other hand came in at Rs 12 bn (up 10.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

More Views on News

Most Popular

6 Charts Showing the State of Indian Financial Markets in 2020(Sector Info)

May 26, 2020

Six charts showing how Indian financial markets have performed in 2020 so far...

Why We Picked This Smallcap Stock for a Post Coronavirus World(Profit Hunter)

May 28, 2020

Covid-19 has made it a survival of the fittest race for many companies. The ones that can adapt will thrive in a post crisis world.

What the RBI's Rate Cut Means for Options Traders(Fast Profits Daily)

May 25, 2020

The RBI governor has cut the repo rate to 4%. What does this mean for options traders? Find out in this video.

Who Will Be Crowned the 'Multibagger Blue Chip' of the Decade?(Profit Hunter)

May 25, 2020

Will the mutlibagger blue chips of the past decade continue to rule the bourses?

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Jun 4, 2020 03:35 PM

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - IPCA LABS COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS